AOCNP EXAM REVIEW 2026 – QUESTIONS AND ANSWERS | VERIFIED AND WELL DETAILED
ANSWERS | PLUS RATIONALES | GUARANTEED PASS | LATEST EXAM UPDATE
Core Domains:
• Pathophysiology and Pharmacology
• Health Promotion and Disease Prevention
• Symptom Management and Palliative Care
• Diagnostic and Therapeutic Procedures
• Oncology Emergencies
• Psychosocial and Behavioral Health
• Professional Practice and Ethics
• Research and Evidence-Based Practice
• Regulatory and Legal Compliance
Introduction
This comprehensive examination is designed to rigorously assess the knowledge and clinical judgment
required for the Advanced Oncology Certified Nurse Practitioner (AOCNP) certification. It evaluates
foundational scientific principles, advanced pathophysiological concepts, and the application of
evidence-based guidelines in complex oncological scenarios. The exam utilizes a multiple-choice
format with a strong emphasis on real-world clinical decision-making, critical thinking, and
prioritization skills. Each question challenges the candidate to synthesize information, interpret
clinical data, and select the most appropriate management strategy, reflecting the multifaceted role of
the oncology NP in delivering high-quality, patient-centered care across the cancer care continuum.
SECTION ONE: QUESTIONS 1 – 100
1. A 62-year-old patient with a history of chronic lymphocytic leukemia (CLL) presents with a
two-week history of progressive fatigue, blurred vision, and a headache that is worse in the
morning. On examination, you note bilateral papilledema. A complete blood count reveals a
white blood cell (WBC) count of 250,000/µL, with 95% lymphocytes. What is the most
appropriate initial intervention?
A. Administer hydroxyurea 500 mg PO twice daily
B. Initiate emergent leukapheresis
C. Order a stat CT scan of the head without contrast
D. Start the patient on allopurinol 300 mg PO daily
🟢B
🔴 Explanation: This patient is presenting with symptoms of leukostasis (hyperviscosity syndrome),
a medical emergency, evidenced by neurologic symptoms and a markedly elevated WBC count. The
most rapid and effective way to immediately lower the WBC count in this setting is emergent
leukapheresis. Hydroxyurea (A) would be part of the treatment plan but takes days to have an
effect. A CT scan (C) is not the priority intervention to address the underlying life-threatening cause.
Allopurinol (D) is given to prevent tumor lysis syndrome, but the immediate, life-threatening
problem is the hyperviscosity.
,2. Which of the following chemotherapy agents is associated with a dose-limiting toxicity of
cumulative, irreversible peripheral neuropathy?
A. Cisplatin
B. Oxaliplatin
C. Vincristine
D. Paclitaxel
🟢A
🔴 Explanation: Cisplatin is well-known for causing a dose-limiting, cumulative, and often
irreversible peripheral neuropathy, particularly in a stocking-glove distribution. While Oxaliplatin (B)
causes a unique acute, cold-induced neuropathy and a cumulative sensory neuropathy, it is often
reversible. Vincristine (C) causes a cumulative, dose-limiting sensorimotor neuropathy, but it is not
classically described as irreversible. Paclitaxel (D) causes a cumulative, dose-limiting sensory
neuropathy, which often resolves upon discontinuation.
3. A patient receiving an immune checkpoint inhibitor (ICI) for metastatic melanoma develops
new-onset, severe watery diarrhea, abdominal cramping, and urgency. A stool culture is negative
for infectious pathogens. What is the most appropriate initial step in management?
A. Initiate loperamide 4 mg PO, then 2 mg after each unformed stool
B. Obtain a flexible sigmoidoscopy to assess for pseudomembranous colitis
C. Discontinue the ICI and start methylprednisolone 1-2 mg/kg/day IV
D. Administer infliximab 5 mg/kg IV
🟢C
🔴 Explanation: This is a classic presentation of immune-mediated colitis, a common and
potentially severe adverse effect of ICIs. The standard of care for grade 3 or 4 colitis is to hold the
ICI and initiate high-dose corticosteroids (e.g., methylprednisolone 1-2 mg/kg/day). Loperamide (A)
should be avoided in this scenario as it can mask symptoms and potentiate ileus in severe colitis. A
flexible sigmoidoscopy (B) would be performed if the diagnosis is uncertain or if the patient is
refractory to steroids. Infliximab (D) is a second-line agent for steroid-refractory colitis.
4. In the context of targeted therapy for Non-Small Cell Lung Cancer (NSCLC), which of the
following biomarkers is most predictive of a clinical response to osimertinib?
A. ALK rearrangement
B. EGFR exon 19 deletion
C. ROS1 fusion
D. BRAF V600E mutation
🟢B
🔴 Explanation: Osimertinib is a third-generation, irreversible EGFR tyrosine kinase inhibitor (TKI)
that is highly effective against sensitizing EGFR mutations, particularly exon 19 deletions and exon
21 L858R point mutations. ALK rearrangements (A) and ROS1 fusions (C) are targeted by different
agents such as alectinib and crizotinib, respectively. BRAF V600E mutations (D) in NSCLC are
targeted with a BRAF/MEK inhibitor combination.
,5. A patient is started on a new oral targeted therapy. Which of the following educational points
is most critical regarding medication adherence and absorption?
A. The medication should be taken on an empty stomach for optimal absorption.
B. If a dose is vomited within 30 minutes of administration, a repeat dose should be taken.
C. The patient must avoid all other prescription and over-the-counter medications.
D. Grapefruit juice must be avoided as it can alter the metabolism and toxicity of the drug.
🟢D
🔴 Explanation: Many oral targeted therapies (e.g., TKIs) are metabolized by the CYP3A4 enzyme
system. Grapefruit juice is a potent inhibitor of CYP3A4, leading to increased drug levels, potentially
exacerbating toxicity. This is a critical patient education point. Absorption may or may not be
affected by food (A), and this is drug-specific. If a patient vomits after taking a dose, it is usually not
recommended to re-dose (B). While interactions are important, it is not practical to avoid all other
medications (C); careful screening for specific interactions is the appropriate practice.
6. An oncology NP is evaluating a patient with anemia receiving a red blood cell transfusion.
Which of the following assessment findings is most indicative of a transfusion-related acute lung
injury (TRALI)?
A. Fever and chills within 1 hour of starting the transfusion
B. Hypotension and hives
C. Acute respiratory distress, hypoxia, and bilateral pulmonary infiltrates
D. Hemoglobinuria and a positive direct antiglobulin test
🟢C
🔴 Explanation: TRALI is characterized by acute onset of respiratory distress, severe hypoxemia, and
non-cardiogenic pulmonary edema (bilateral infiltrates on CXR) within 6 hours of transfusion. Fever
and chills (A) are common in febrile non-hemolytic reactions. Hypotension and hives (B) suggest a
simple allergic reaction. Hemoglobinuria and a positive direct antiglobulin test (D) are classic signs
of a hemolytic transfusion reaction.
7. A patient with stage IV breast cancer with bone metastases is prescribed denosumab 120 mg
subcutaneously. As part of the initial assessment, which laboratory value is most critical to
evaluate and monitor?
A. Serum creatinine
B. Serum calcium
C. Serum phosphorus
D. Serum magnesium
🟢B
🔴 Explanation: Denosumab is a RANK ligand inhibitor used to prevent skeletal-related events. A
significant adverse effect is hypocalcemia. Therefore, baseline and periodic monitoring of serum
calcium is essential, especially in patients with a predisposition to low calcium. Patients must also be
supplemented with calcium and Vitamin D. While creatinine (A), phosphorus (C), and magnesium
(D) may be monitored, calcium is the most critical.
, 8. A 45-year-old patient with a history of chemotherapy-induced nausea and vomiting (CINV) is
starting a highly emetogenic chemotherapy regimen. Which of the following antiemetic
regimens is considered guideline-recommended for prophylaxis?
A. Ondansetron and dexamethasone
B. Aprepitant, ondansetron, and dexamethasone
C. Olanzapine and dexamethasone
D. Metoclopramide and diphenhydramine
🟢B
🔴 Explanation: The standard of care for the prophylaxis of CINV in patients receiving highly
emetogenic chemotherapy is a three-drug combination of a neurokinin-1 (NK1) receptor
antagonist (e.g., aprepitant), a 5-HT3 receptor antagonist (e.g., ondansetron), and dexamethasone
(a corticosteroid). Option A lacks an NK1 antagonist. Option C (Olanzapine and dexamethasone) is
also an effective regimen, but the NK1/5-HT3/steroid combination is the most widely established
and guideline-preferred triple therapy for HEC. Option D is an outdated regimen for breakthrough
nausea.
9. A patient is diagnosed with early-stage HER2-positive breast cancer and is being evaluated for
adjuvant therapy. In addition to chemotherapy, which targeted agent has demonstrated a
significant survival benefit in this setting?
A. Trastuzumab
B. Pertuzumab
C. T-DM1
D. Lapatinib
🟢A
🔴 Explanation: Trastuzumab is the foundational targeted therapy for HER2-positive breast cancer.
When added to adjuvant chemotherapy, it significantly reduces the risk of recurrence and improves
overall survival. Pertuzumab (B) is used in the neoadjuvant and metastatic settings, often with
trastuzumab and chemotherapy. T-DM1 (C) is an antibody-drug conjugate used primarily in the
metastatic setting and as adjuvant therapy for residual disease after neoadjuvant therapy. Lapatinib
(D) is a small molecule TKI used in later-line metastatic settings.
10. The oncology nurse practitioner is performing a comprehensive survivorship assessment for
a patient 5 years post-treatment for Hodgkin lymphoma who received mantle field radiation.
Which of the following screening recommendations is most appropriate regarding
cardiovascular risk?
A. Annual echocardiogram
B. Stress echocardiogram only if symptomatic
C. Baseline echocardiogram with ongoing surveillance as clinically indicated
D. Cardiac CT for coronary artery calcification
🟢C
🔴 Explanation: Patients who received mediastinal radiation (mantle field) are at significantly
increased long-term risk for cardiovascular disease, including coronary artery disease and valvular
dysfunction. The recommendation is for a baseline comprehensive echocardiogram 5-10 years
ANSWERS | PLUS RATIONALES | GUARANTEED PASS | LATEST EXAM UPDATE
Core Domains:
• Pathophysiology and Pharmacology
• Health Promotion and Disease Prevention
• Symptom Management and Palliative Care
• Diagnostic and Therapeutic Procedures
• Oncology Emergencies
• Psychosocial and Behavioral Health
• Professional Practice and Ethics
• Research and Evidence-Based Practice
• Regulatory and Legal Compliance
Introduction
This comprehensive examination is designed to rigorously assess the knowledge and clinical judgment
required for the Advanced Oncology Certified Nurse Practitioner (AOCNP) certification. It evaluates
foundational scientific principles, advanced pathophysiological concepts, and the application of
evidence-based guidelines in complex oncological scenarios. The exam utilizes a multiple-choice
format with a strong emphasis on real-world clinical decision-making, critical thinking, and
prioritization skills. Each question challenges the candidate to synthesize information, interpret
clinical data, and select the most appropriate management strategy, reflecting the multifaceted role of
the oncology NP in delivering high-quality, patient-centered care across the cancer care continuum.
SECTION ONE: QUESTIONS 1 – 100
1. A 62-year-old patient with a history of chronic lymphocytic leukemia (CLL) presents with a
two-week history of progressive fatigue, blurred vision, and a headache that is worse in the
morning. On examination, you note bilateral papilledema. A complete blood count reveals a
white blood cell (WBC) count of 250,000/µL, with 95% lymphocytes. What is the most
appropriate initial intervention?
A. Administer hydroxyurea 500 mg PO twice daily
B. Initiate emergent leukapheresis
C. Order a stat CT scan of the head without contrast
D. Start the patient on allopurinol 300 mg PO daily
🟢B
🔴 Explanation: This patient is presenting with symptoms of leukostasis (hyperviscosity syndrome),
a medical emergency, evidenced by neurologic symptoms and a markedly elevated WBC count. The
most rapid and effective way to immediately lower the WBC count in this setting is emergent
leukapheresis. Hydroxyurea (A) would be part of the treatment plan but takes days to have an
effect. A CT scan (C) is not the priority intervention to address the underlying life-threatening cause.
Allopurinol (D) is given to prevent tumor lysis syndrome, but the immediate, life-threatening
problem is the hyperviscosity.
,2. Which of the following chemotherapy agents is associated with a dose-limiting toxicity of
cumulative, irreversible peripheral neuropathy?
A. Cisplatin
B. Oxaliplatin
C. Vincristine
D. Paclitaxel
🟢A
🔴 Explanation: Cisplatin is well-known for causing a dose-limiting, cumulative, and often
irreversible peripheral neuropathy, particularly in a stocking-glove distribution. While Oxaliplatin (B)
causes a unique acute, cold-induced neuropathy and a cumulative sensory neuropathy, it is often
reversible. Vincristine (C) causes a cumulative, dose-limiting sensorimotor neuropathy, but it is not
classically described as irreversible. Paclitaxel (D) causes a cumulative, dose-limiting sensory
neuropathy, which often resolves upon discontinuation.
3. A patient receiving an immune checkpoint inhibitor (ICI) for metastatic melanoma develops
new-onset, severe watery diarrhea, abdominal cramping, and urgency. A stool culture is negative
for infectious pathogens. What is the most appropriate initial step in management?
A. Initiate loperamide 4 mg PO, then 2 mg after each unformed stool
B. Obtain a flexible sigmoidoscopy to assess for pseudomembranous colitis
C. Discontinue the ICI and start methylprednisolone 1-2 mg/kg/day IV
D. Administer infliximab 5 mg/kg IV
🟢C
🔴 Explanation: This is a classic presentation of immune-mediated colitis, a common and
potentially severe adverse effect of ICIs. The standard of care for grade 3 or 4 colitis is to hold the
ICI and initiate high-dose corticosteroids (e.g., methylprednisolone 1-2 mg/kg/day). Loperamide (A)
should be avoided in this scenario as it can mask symptoms and potentiate ileus in severe colitis. A
flexible sigmoidoscopy (B) would be performed if the diagnosis is uncertain or if the patient is
refractory to steroids. Infliximab (D) is a second-line agent for steroid-refractory colitis.
4. In the context of targeted therapy for Non-Small Cell Lung Cancer (NSCLC), which of the
following biomarkers is most predictive of a clinical response to osimertinib?
A. ALK rearrangement
B. EGFR exon 19 deletion
C. ROS1 fusion
D. BRAF V600E mutation
🟢B
🔴 Explanation: Osimertinib is a third-generation, irreversible EGFR tyrosine kinase inhibitor (TKI)
that is highly effective against sensitizing EGFR mutations, particularly exon 19 deletions and exon
21 L858R point mutations. ALK rearrangements (A) and ROS1 fusions (C) are targeted by different
agents such as alectinib and crizotinib, respectively. BRAF V600E mutations (D) in NSCLC are
targeted with a BRAF/MEK inhibitor combination.
,5. A patient is started on a new oral targeted therapy. Which of the following educational points
is most critical regarding medication adherence and absorption?
A. The medication should be taken on an empty stomach for optimal absorption.
B. If a dose is vomited within 30 minutes of administration, a repeat dose should be taken.
C. The patient must avoid all other prescription and over-the-counter medications.
D. Grapefruit juice must be avoided as it can alter the metabolism and toxicity of the drug.
🟢D
🔴 Explanation: Many oral targeted therapies (e.g., TKIs) are metabolized by the CYP3A4 enzyme
system. Grapefruit juice is a potent inhibitor of CYP3A4, leading to increased drug levels, potentially
exacerbating toxicity. This is a critical patient education point. Absorption may or may not be
affected by food (A), and this is drug-specific. If a patient vomits after taking a dose, it is usually not
recommended to re-dose (B). While interactions are important, it is not practical to avoid all other
medications (C); careful screening for specific interactions is the appropriate practice.
6. An oncology NP is evaluating a patient with anemia receiving a red blood cell transfusion.
Which of the following assessment findings is most indicative of a transfusion-related acute lung
injury (TRALI)?
A. Fever and chills within 1 hour of starting the transfusion
B. Hypotension and hives
C. Acute respiratory distress, hypoxia, and bilateral pulmonary infiltrates
D. Hemoglobinuria and a positive direct antiglobulin test
🟢C
🔴 Explanation: TRALI is characterized by acute onset of respiratory distress, severe hypoxemia, and
non-cardiogenic pulmonary edema (bilateral infiltrates on CXR) within 6 hours of transfusion. Fever
and chills (A) are common in febrile non-hemolytic reactions. Hypotension and hives (B) suggest a
simple allergic reaction. Hemoglobinuria and a positive direct antiglobulin test (D) are classic signs
of a hemolytic transfusion reaction.
7. A patient with stage IV breast cancer with bone metastases is prescribed denosumab 120 mg
subcutaneously. As part of the initial assessment, which laboratory value is most critical to
evaluate and monitor?
A. Serum creatinine
B. Serum calcium
C. Serum phosphorus
D. Serum magnesium
🟢B
🔴 Explanation: Denosumab is a RANK ligand inhibitor used to prevent skeletal-related events. A
significant adverse effect is hypocalcemia. Therefore, baseline and periodic monitoring of serum
calcium is essential, especially in patients with a predisposition to low calcium. Patients must also be
supplemented with calcium and Vitamin D. While creatinine (A), phosphorus (C), and magnesium
(D) may be monitored, calcium is the most critical.
, 8. A 45-year-old patient with a history of chemotherapy-induced nausea and vomiting (CINV) is
starting a highly emetogenic chemotherapy regimen. Which of the following antiemetic
regimens is considered guideline-recommended for prophylaxis?
A. Ondansetron and dexamethasone
B. Aprepitant, ondansetron, and dexamethasone
C. Olanzapine and dexamethasone
D. Metoclopramide and diphenhydramine
🟢B
🔴 Explanation: The standard of care for the prophylaxis of CINV in patients receiving highly
emetogenic chemotherapy is a three-drug combination of a neurokinin-1 (NK1) receptor
antagonist (e.g., aprepitant), a 5-HT3 receptor antagonist (e.g., ondansetron), and dexamethasone
(a corticosteroid). Option A lacks an NK1 antagonist. Option C (Olanzapine and dexamethasone) is
also an effective regimen, but the NK1/5-HT3/steroid combination is the most widely established
and guideline-preferred triple therapy for HEC. Option D is an outdated regimen for breakthrough
nausea.
9. A patient is diagnosed with early-stage HER2-positive breast cancer and is being evaluated for
adjuvant therapy. In addition to chemotherapy, which targeted agent has demonstrated a
significant survival benefit in this setting?
A. Trastuzumab
B. Pertuzumab
C. T-DM1
D. Lapatinib
🟢A
🔴 Explanation: Trastuzumab is the foundational targeted therapy for HER2-positive breast cancer.
When added to adjuvant chemotherapy, it significantly reduces the risk of recurrence and improves
overall survival. Pertuzumab (B) is used in the neoadjuvant and metastatic settings, often with
trastuzumab and chemotherapy. T-DM1 (C) is an antibody-drug conjugate used primarily in the
metastatic setting and as adjuvant therapy for residual disease after neoadjuvant therapy. Lapatinib
(D) is a small molecule TKI used in later-line metastatic settings.
10. The oncology nurse practitioner is performing a comprehensive survivorship assessment for
a patient 5 years post-treatment for Hodgkin lymphoma who received mantle field radiation.
Which of the following screening recommendations is most appropriate regarding
cardiovascular risk?
A. Annual echocardiogram
B. Stress echocardiogram only if symptomatic
C. Baseline echocardiogram with ongoing surveillance as clinically indicated
D. Cardiac CT for coronary artery calcification
🟢C
🔴 Explanation: Patients who received mediastinal radiation (mantle field) are at significantly
increased long-term risk for cardiovascular disease, including coronary artery disease and valvular
dysfunction. The recommendation is for a baseline comprehensive echocardiogram 5-10 years
